ASCO GU 2022: What to watch out for in renal
ASCO GU 2022: What to watch out for in renal
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Quality of life and patient perspectives in renal cell carcinoma
Comparison of health access, lifestyle, prostate cancer knowledge, and screening among black men residing in West Africa and the USA
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Cancer Health Disparities Special Issue - Editorial
ESMO 2021: PARPi data and their role in mono/combination therapies